Back
Bellevue Life Sciences Acquisition 10K Form
Sell
32
BLAC
Bellevue Life Sciences Acquisition
Last Price:
10.91
Seasonality Move:
0.77%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive BLAC News And Ratings
See the #1 stock for the next 7 days that we like better than BLAC
BLAC Financial Statistics
Sales & Book Value
| Annual Sales: | -- |
|---|---|
| Cash Flow: | $-1.42M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $3.75 |
| Price / Book: | 2.91 |
Profitability
| EPS (TTM): | -0.03000 |
|---|---|
| Net Income (TTM): | $-165.7K |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Bellevue Life Sciences Acquisition Earnings Forecast
Key Bellevue Life Sciences Acquisition Financial Ratios
- Per Share Earnings over the last 3 years have been positive in 1 years.
Bellevue Life Sciences Acquisition Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Current Symbol: | BLAC |
| Website: | bellevuespac.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 217.8 |
|---|---|
| Forward P/E Ratio: | 0 |
BLAC Technical Analysis vs Fundamental Analysis
Sell
32
Bellevue Life Sciences Acquisition (BLAC)
is a Sell
Is Bellevue Life Sciences Acquisition a Buy or a Sell?
-
Bellevue Life Sciences Acquisition stock is rated a Sell
The current Bellevue Life Sciences Acquisition [BLAC] share price is $10.89. The Score for BLAC is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.